Risk

PROMETHEUS® Celiac PLUS provides more comprehensive, accurate answers

  • Only Prometheus genetic testing quantifies the relative risk of disease for every patient

  • Clear risk stratification may enable you to prevent disease onset

  • A negative predictive value (NPV) of 95% to 100% allows you to rule out celiac disease for life2



Now you can assess your patients' risk

Category Number
DQ Genotype Category
Increased Risk Over
General Population3,4
Relative Risk
8
DQ2 homozygous
31x
Extremely high
7
DQ2/other high-risk gene
16x
Very high
6
DQ2/DQ8
10x
Very high
5
DQ8 homozygous
10x
High
4
DQ2 heterozygous
10x
High
3
DQ8 heterozygous
2x
Moderate
2
DQ2/other low-risk gene
< 1x
Low
1
DQ2-, DQ8-
< 0.1x
Extremely low

Most celiac patients carry either the DQ2 haplotype (about 95% of celiacs) or the DQ8 haplotype (about 5% of celiacs).
There are two DQ2 haplotypes, but only one DQ8 haplotype—specific combinations may confer different risks
for the development of celiac disease, as shown above.


References:

2. Kaukinen K, Partanen J, Mäki M, Collin P. HLA-DQ typing in the diagnosis of celiac disease. Am J Gastroenterol. 2002;97(3):695-699.
3. Pietzak M, Schofield T. HLA-DQ2 homozygotes are associated with a 31-fold increased risk of EMA positivety in a large sample of sera (n = 4152) from patients at risk for celiac disease [DDW abstract]. Gastroenterology. 2007;132(7):2585.
4. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003;163(3):286-292.